These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38812251)

  • 1. Testosterone therapy over 60 months improves aging male symptoms scores in all men with adult-onset testosterone deficiency.
    Haider KS; Zitzmann M; Ramachandran P; König CS; Hackett G; Haider A; Saad F; Desnerck P; Strange R; Mann A; Ramachandran S
    Aging Male; 2024 Dec; 27(1):2357548. PubMed ID: 38812251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone therapy reduces insulin resistance in men with adult-onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open-label phase.
    Tishova Y; Kalinchenko S; Mskhalaya G; Hackett G; Livingston M; König C; Strange R; Zitzmann M; Mann A; Maarouf A; Ramachandran S
    Diabetes Obes Metab; 2024 Jun; 26(6):2147-2157. PubMed ID: 38433502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone replacement therapy: association with mortality in high-risk patient subgroups.
    Mann A; Strange RC; König CS; Hackett G; Haider A; Haider KS; Desnerck P; Ramachandran S
    Andrology; 2024 Sep; 12(6):1389-1397. PubMed ID: 38148671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
    Yassin DJ; Doros G; Hammerer PG; Yassin AA
    J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone Replacement Therapy: Effects on Blood Pressure in Hypogonadal Men.
    Hackett G; Mann A; Haider A; Haider KS; Desnerck P; König CS; Strange RC; Ramachandran S
    World J Mens Health; 2024 Oct; 42(4):749-761. PubMed ID: 38449452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
    Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
    Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
    Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
    Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.
    Meuleman EJ; Legros JJ; Bouloux PM; Johnson-Levonas AO; Kaspers MJ; Elbers JM; Geurts TB; Meehan AG;
    Aging Male; 2015; 18(3):157-63. PubMed ID: 26030346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
    Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
    Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone undecanoate improves lipid profile in patients with type 1 diabetes and hypogonadotrophic hypogonadism.
    Chillarón JJ; Fernández-Miró M; Albareda M; Fontserè S; Colom C; Vila L; Pedro-Botet J; Flores Le-Roux JA
    Endocr J; 2016 Sep; 63(9):849-855. PubMed ID: 27452372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
    Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
    J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
    Dimitriadis GK; Randeva HS; Aftab S; Ali A; Hattersley JG; Pandey S; Grammatopoulos DK; Valsamakis G; Mastorakos G; Jones TH; Barber TM
    Endocrine; 2018 Apr; 60(1):175-184. PubMed ID: 29396841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement therapy: Pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups.
    Ramachandran S; Hackett GI; Strange RC
    Andrology; 2020 Sep; 8(5):1222-1232. PubMed ID: 32384175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.
    Swerdloff RS; Wang C; White WB; Kaminetsky J; Gittelman MC; Longstreth JA; Dudley RE; Danoff TM
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2515-31. PubMed ID: 32382745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.